Azzad Asset Management’s United Therapeutics UTHR Stock Holding History

Azzad Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,408	Closed	-$589K	–	323
2018 Q4	$589K	Sell	5,408 -121	-2%	-$14K	0.2%	187
2018 Q3	$707K	Buy	5,529 +18	+0.3%	+$2.23K	0.19%	193
2018 Q2	$624K	Buy	5,511 +2,610	+90%	+$287K	0.18%	203
2018 Q1	$326K	Buy	2,901 +162	+6%	+$20.6K	0.1%	262
2017 Q4	$405K	Buy	2,739 +42	+2%	+$5.34K	0.13%	225
2017 Q3	$316K	Buy	2,697 +34	+1%	+$4.34K	0.11%	259
2017 Q2	$345K	Buy	2,663 +144	+6%	+$18K	0.12%	234
2017 Q1	$341K	Buy	+2,519	New	+$382K	0.13%	224
2014 Q2	–	Sell	-7,428	Closed	-$673K	–	290
2014 Q1	$673K	Hold	7,428	–	–	0.44%	83
2013 Q4	$840K	Hold	7,428	–	–	0.61%	37
2013 Q3	$586K	Hold	7,428	–	–	0.48%	71
2013 Q2	$489K	Buy	+7,428	New	+$479K	0.42%	92

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Azzad Asset Management's UTHR Position: Q1 2019 in Review

Azzad Asset Management sold out of United Therapeutics (UTHR) in Q1 2019, closing a stake of 5,408 shares — an estimated $589K sold.

Azzad Asset Management first reported a position in UTHR in Q2 2013 and held it in 12 quarters. The position peaked at $840K in Q4 2013. 378 funds tracked by Wall St. Rank hold UTHR as of Q1 2019.

Azzad Asset Management reported no remaining United Therapeutics position as of Q1 2019 after selling out during the quarter.
Azzad Asset Management sold 5,408 United Therapeutics shares in Q1 2019, an estimated $589K.
Azzad Asset Management first reported a position in United Therapeutics in Q2 2013 and held it in 12 quarters.
Azzad Asset Management's United Therapeutics position peaked at $840K in Q4 2013.
378 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2019.

Based on Azzad Asset Management's 13F filing for Q1 2019, filed 1 Apr 2024.